MustGrow Biologics Corp. Announces Results of Shareholder Meeting
- Shareholders approved the number of directors at seven and elected all director nominees. The vote percentage was high, with Corey Giasson receiving 99.20% of votes, Colin Bletsky receiving 99.62% of votes, Brad Munro receiving 99.62% of votes, Thomas Flow receiving 96.74% of votes, Matt Kowalski receiving 99.62% of votes, David Borecky receiving 99.65% of votes, and Laura Westby receiving 99.94% of votes. The reappointment of auditors and approval of the Omnibus Plan indicate stability and confidence in the company's governance and financial management.
- None.
Saskatoon, Saskatchewan--(Newsfile Corp. - June 29, 2023) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its 2023 annual meeting of shareholders (the "Meeting") held on June 29, 2023. At the Meeting, shareholders approved the setting of the number of directors of the Company at seven and all director nominees listed in the Company's management information circular dated May 31, 2023 were elected as directors of the Company on a vote held by ballot. The results of the ballot were as follows:
| Director | Vote Type | Number of Votes | Percentage of Votes |
| Corey Giasson | For | 8,958,408 | |
| Withheld | 72,412 | ||
| Colin Bletsky | For | 8,996,698 | |
| Withheld | 34,122 | ||
| Brad Munro | For | 8,996,698 | |
| Withheld | 34,122 | ||
| Thomas Flow | For | 8,736,398 | |
| Withheld | 294,422 | ||
| Matt Kowalski | For | 8,996,698 | |
| Withheld | 34,122 | ||
| David Borecky | For | 8,998,898 | |
| Withheld | 31,922 | ||
| Laura Westby | For | 9,025,298 | |
| Withheld | 5,522 |
In addition, shareholders approved the reappointment of Ersnt & Young LLP, Chartered Professional Accountants, as the Company's auditors and authorized the directors of the Company to fix their remuneration, and reapproved the Company's omnibus equity incentive plan (the "Omnibus Plan"). Having received shareholder approval, the Company's Omnibus Plan remains subject to final approval from the TSX Venture Exchange.
The formal report on voting results with respect to all matters voted upon at the Meeting will be filed on SEDAR under www.sedar.com.
---------
About MustGrow
MustGrow is an agriculture biotech company developing organic biopesticides and bioherbicides by harnessing the natural defense mechanism of the mustard plant to protect the global food supply from diseases, insect pests, and weeds. MustGrow and its leading global partners - Janssen PMP (pharmaceutical division of Johnson & Johnson), Bayer, Sumitomo Corporation, and Univar Solutions' NexusBioAg - are developing mustard-based organic solutions to potentially replace harmful synthetic chemicals. Over 150 independent tests have been completed, validating MustGrow's safe and effective approach to crop and food protection. Pending regulatory approval, MustGrow's patented liquid products could be applied through injection, standard drip, or spray equipment, improving functionality and performance features. Now a platform technology, MustGrow and its global partners are pursuing applications in several different industries from preplant soil treatment and weed control, to postharvest disease control and food preservation. MustGrow has approximately 49.7 million basic common shares issued and outstanding and 55.6 million shares fully diluted. For further details, please visit www.mustgrow.ca.
ON BEHALF OF THE BOARD
"Corey Giasson"
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca
© 2023 MustGrow Biologics Corp. All rights reserved.
MustGrow Forward-Looking Statements
Certain statements included in this press release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the preferences and choices of agricultural regulators with respect to product approval timelines; (ii) the ability of MustGrow's partners to meet obligations under their respective agreements; and (iii) other risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2022 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/171900
FAQ
What were the results of MustGrow Biologics Corp.'s 2023 annual meeting of shareholders?
What percentage of votes did each director nominee receive?
What did shareholders approve besides the number of directors?
What is the Omnibus Plan?
